Antibody‐induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c‐erbb‐2 (her‐2/neu) gene product p185

Over‐expression of the c‐erbB‐2 (HER‐2/neu) gene product p185 occurs in 30% of breast and ovarian cancers. The p185 protein might serve as a target for serotherapy in that antibodies against different epitopes on the extracellular domain of p185 can inhibit growth of tumor cells in the absence of cellular or humoral effector mechanisms. To define epitopes of functional relevance, II monoclonal antibodies (MAbs) were evaluated for their ability to bind to the extracellular domain of p185. Results of competition studies with 1251‐labeled and non‐labeled antibodies indicated that 10 of 11 epitopes were grouped in a linear array. Antibodies against 7 epitopes inhibited anchorageindependent growth and antibodies against 2 of these epitopes also inhibited anchorage‐dependent growth of SKBr3 breast‐cancer cells that over‐expressed p185. Treatment with antibodies exerted cytotoxic rather than cytostatic effects. When antibodies were used in combination, additive or supra‐additive inhibition of anchorage‐independent and anchorage‐dependent growth was observed between pairs of antibodies. Growth inhibition did not relate to the affinity of the antibody or its isotype. Two antibodies that inhibited both anchorage‐dependent and anchorage‐independent growth also blocked binding of the HER‐2/neu ligand, whereas 5 antibodies that inhibited only anchorage‐independent growth had no effect on ligand binding. Inhibition of cell growth did not correlate with internalization of p185 or down‐regulation of p185 on the cell surface. Fab fragments of active antibodies could also inhibit anchorage‐independent growth of SKBr3. Thus, murine MAbs and their fragments recognized both immunochemically distinct and functionally distinct epitopes on the p185 molecule. Whereas inhibition of anchorage‐dependent growth correlated with the ability of antibodies to block ligand binding, inhibition of anchorage‐independent growth did not correlate with effects on ligand binding, internalization, cell‐surface expression or cross‐linking of pl85.

[1]  R. Weinberg,et al.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. , 1985, Science.

[2]  W. Carney,et al.  Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. , 1989, Oncogene.

[3]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[4]  A. Ullrich,et al.  Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Saxena,et al.  Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2. , 1991, Molecular immunology.

[6]  G A McPherson,et al.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. , 1985, Journal of pharmacological methods.

[7]  G A McPherson,et al.  A practical computer-based approach to the analysis of radioligand binding experiments. , 1983, Computer programs in biomedicine.

[8]  J. Mendelsohn,et al.  Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. , 1989, Cancer research.

[9]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[10]  Y. Yarden,et al.  Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Bast,et al.  The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. , 1993, American journal of obstetrics and gynecology.

[12]  R. Bast,et al.  Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. , 1991, Cancer research.

[13]  J. Fogh,et al.  New Human Tumor Cell Lines , 1975 .

[14]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[15]  R. Bast,et al.  A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast‐cancer cell lines , 1992, International journal of cancer.

[16]  A. Frankel,et al.  Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. , 1985, Cancer research.

[17]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[18]  R. Lupu,et al.  Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. , 1990, Science.

[19]  J. Mendelsohn,et al.  Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. , 1984, Cancer research.

[20]  S. White,et al.  Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. , 1990, Cancer research.

[21]  M. Greene,et al.  Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. , 1988, Oncogene.

[22]  Yosef Yarden,et al.  Isolation of the Neu HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells , 1992, Cell.

[23]  R. Lupu,et al.  Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[25]  S. George,et al.  Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. , 1990, Cancer research.

[26]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[27]  Robert A. Weinberg,et al.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies , 1985, Cell.